The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3

The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3–4 CKD

Published:2019-12-09 Issue:3 Volume:23 Page:308-315
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Kalantar-Zadeh Kamyar¹,Hollenbeak Christopher S.²,Arguello Roy³,Snyder Sophie³,Ashfaq Akhtar⁴

Affiliation:

1. Division of Nephrology, University of California Irvine, School of Medicine, Orange, CA, USA;

2. Department of Health Policy and Administration, College of Health and Human Development, The Pennsylvania State University, University Park, PA, USA;

3. Health Economics and Outcomes Research, BluePath Solutions, Los Angeles, CA, USA;

4. Renal Division, OPKO Health Inc., Miami, FL, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1693385

Reference52 articles.

1. Centers for Disease Control and Prevention. National chronic kidney disease fact sheet; 2017 [accessed 2019 Jan 8]. https://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf

2. Diagnosis and Treatment of Osteoporosis in Chronic Renal Disease

3. Mechanisms of Anemia in CKD

4. Association between Parathyroid Hormone and Cardiovascular Disease

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction of Vitamin D Levels in Patients with Diagnosed Chronic Kidney Disease;INT TRANS J ENG MANA;2022

2. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis;Frontiers in Public Health;2021-07-21